Rising to the challenges of rare disease treatment
Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

T-cell Image

Specialized BioTherapeutics Pipeline

Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.

PreclinicalPhase 1Phase 2Phase 3Market
HyBryte™ for Cutaneous T-Cell Lymphoma (CTCL)
Preclinical
Phase 1
Phase 2
Phase 3
Market
SGX942 for Oral Mucositis Treatment
Preclinical
Phase 1
Phase 2
Phase 3
Market
SGX203 for Pediatric Crohn’s Disease
Preclinical
Phase 1
Phase 2
Phase 3
Market
SGX201 for Radiation Enteritis Treatment
Preclinical
Phase 1
Phase 2
Phase 3
Market

Orphan and/or Fast Track Designation

Denotes funding by NIH, BARDA, DTRA and/or FDA.

Public Health Solutions Pipeline

Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.

Proof-of-ConceptINDPhase 1Phase 2/3Market
RiVax® to Prevent Ricin Poisoning
Proof-of-Concept
IND
Phase 1
Phase 2/3
Market
SGX943 for Infectious Disease
Proof-of-Concept
IND
Phase 1
Phase 2/3
Market
ThermoVax®: Thermostabilized Vaccines for Global Use
Proof-of-Concept
IND
Phase 1
Phase 2/3
Market

Orphan and/or Fast Track Designation

Denotes funding by NIH, BARDA, DTRA and/or FDA.
Papers and chars with medical data

Corporate Presentation

June 28, 2021 Corporate Presentation
Papers and chars with medical data

Featured Video

Dr. Ellen Kim Featured on OncologyTube

Stay on top of the latest Soligenix news

Subscribe To Our Newsletter